Artelo Biosciences, Inc.
ARTL
$1.95
$0.3018.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.26% | 10.51% | -5.42% | -2.81% | -19.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.35% | -3.82% | -3.22% | 1.79% | -6.20% |
| Operating Income | -30.35% | 3.82% | 3.22% | -1.79% | 6.20% |
| Income Before Tax | -36.95% | -0.62% | -1.16% | -5.78% | 4.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.95% | -0.62% | -1.16% | -5.78% | 4.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.95% | -0.62% | -1.16% | -5.78% | 4.54% |
| EBIT | -30.35% | 3.82% | 3.22% | -1.79% | 6.20% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -20.91% | 7.24% | 9.66% | 7.43% | 19.17% |
| Normalized Basic EPS | -15.98% | 10.90% | 13.80% | 11.00% | 20.54% |
| EPS Diluted | -20.91% | 7.24% | 9.66% | 7.45% | 19.19% |
| Normalized Diluted EPS | -15.98% | 10.90% | 13.80% | 11.00% | 20.54% |
| Average Basic Shares Outstanding | 5.51% | -23.49% | -38.79% | -37.73% | -36.50% |
| Average Diluted Shares Outstanding | 5.51% | -23.49% | -38.79% | -37.73% | -36.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |